Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Good news for CRP assays

December 5, 2008

Analysis of:CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com

The findings of the Jupiter trial will not only boost the use of rosuvastatin as an evidence-based therapy, but also the prescription of C-Reactive protein, with probably high benefits for companies selling CRP assays.

Poise Trial: more challenging questions than answers

June 19, 2008

Analysis of:Higher Risk of Death and Stroke in Patients Given Beta Blockers After Non-Cardiac Surgery (POISE Trial) | pharmalive.com

The POISE trial showed an excess risk of stroke after general surgery, counter-balancing the beneficial effects of IV metoprolol, a betablocker, to protect the heart of a post-operative myocardial infarction. With the population ageing and the growing epidemics of risk factors for cardiovascular diseases (CVD), the protection of the cardiovascular system from an acute event during non-cardiac surgery is of growing concern. The results of POISE trial challenge other results reported elsewhere (e.g. Decrease trials) suggesting a cardiac protective effect of betablockers in this setting. Contrasting results in these trials might be related to the drug used, as well as the dosage and administration modes, but the most probable difference is related to the study population. An adequate selection of patients at higher risk of post-operative CVD events are probably the key factor. Other drugs able to slow the heart rate without affecting blood pressure, such as ivabradine might be promising.

Page : 11 to 2 of 2

Subscribe to Updates

By RSS